Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sutro Biopharma Inc STRO

Healthcare Biotechnology
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed... see more

Recent & Breaking News (NDAQ:STRO)

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire April 29, 2022

Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022

PR Newswire April 8, 2022

Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference

PR Newswire April 5, 2022

Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC

PR Newswire March 30, 2022

Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference

PR Newswire March 3, 2022

Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones

PR Newswire February 28, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

Newsfile February 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

Newsfile February 2, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

PR Newswire January 27, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

Newsfile January 25, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

Newsfile January 19, 2022

SHAREHOLDER ALERT: Investigation of Sutro Biopharma, Inc. Announced by Holzer & Holzer, LLC

Newsfile January 18, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

PR Newswire January 17, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

Newsfile January 11, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

PR Newswire January 7, 2022

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

PR Newswire January 6, 2022

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

PR Newswire January 5, 2022

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

PR Newswire December 27, 2021

Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer

PR Newswire December 27, 2021

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021

PR Newswire December 13, 2021